Blog
Articles on research peptides — storage, quality and practical know-how.
Melanotan II: History, Mechanism and Research Explained
In this article, we look at how Melanotan II works, what the key studies showed and how research on it contributed to three FDA-approved drugs.
PT-141: Mechanism of Action and Clinical Research
PT-141 (bremelanotide) is a synthetic peptide that acts as an agonist of melanocortin receptors in the brain and is studied in relation to sexual desire and arousal. This article summarizes how PT-141 works at the molecular level, how its clinical research program has proceeded, and what published studies specifically show in both women and men.
Fragment 176-191: Mechanism of Action and Study Overview
Fragment 176-191 is a short peptide derived from the C-terminal portion of human growth hormone, studied for its effect on fat-cell metabolism. Clinical studies in humans were conducted with its modified version, AOD9604 — the article explains what can and cannot be concluded from them. This article summarizes how Fragment 176-191 works, what studies to date have specifically shown, and in what forms it is used in research.
GHK-Cu: What Clinical Studies Actually Show
GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) is among the longest and best-documented peptides in tissue-regeneration research — unlike many newer molecules, it has more than fifty years of published research behind it. It falls primarily within the cosmetic and dermatological space, where it appears in products aimed at skin and hair. This article summarizes what GHK-Cu is, how it works, what clinical studies have specifically shown — including their limitations — and in what forms it is used in research.
BPC-157: Vast Animal Data, Thin Human Evidence
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from part of a protein naturally found in human gastric juice. It's among the most heavily studied peptides in tissue-regeneration research — hundreds of preclinical papers exist — but it's important to know that the overwhelming majority of that data comes from animal and cell-culture models, not human clinical trials. This article summarizes what BPC-157 is, how it works, what preclinical versus human studies specifically show, and its current regulatory status.
Retatrutide: Mechanism of Action and Trial Results
Retatrutide (development code LY3437943) is an experimental peptide compound developed by the pharmaceutical company Eli Lilly, and it ranks among the most closely watched molecules in current metabolic research. In clinical trials, it has produced one of the largest reductions in body weight ever recorded for a compound in its class. This article summarizes what retatrutide is, how it works, what positive and adverse effects trials to date have shown, and in what forms it is used in research and laboratory practice.